Anebulo Pharmaceuticals Inc.
ANEB | OTC
$1.12
+$0.25 (+28.74%)
At close: Mar 18, 2026, 3:46 PM ET
Company Profile
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
Key Executives
| Name | Position |
|---|---|
| Richard Cunningham | Chief Executive Officer & Director |
| Daniel V. George | Acting Chief Financial Officer & Secretary |
| Joseph F. Lawler | Founder & Chairman |
| Kenneth C. Cundy | Chief Scientific Officer |
Anebulo Pharmaceuticals Inc.
| Country | United States |
| IPO Date | May 6, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Richard Anthony Cunningham |
Contact Details
1415 Ranch Road 620 South Lakeway,
Texas 78734 United States
Stock Details
| Ticker Symbol | ANEB |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001815974 |
| CUSIP Number | 034569103 |
| ISIN Number | US0345691036 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove ANEB